Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression

被引:35
|
作者
Kuge, Y [1 ]
Katada, Y
Shimonaka, S
Temma, T
Kimura, H
Kiyono, Y
Yokota, C
Minematsu, K
Seki, K
Tamaki, N
Ohkura, K
Saji, H
机构
[1] Kyoto Univ, Grad Sch Pharmceut Sci, Dept Pathofunct Bioanal, Kyoto, Japan
[2] Kyoto Univ Hosp, Fac Med, Radioisotopes Res Lab, Kyoto 6068507, Japan
[3] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[4] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[5] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[6] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[7] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan
[8] Hokkaido Univ, Fac Pharmaceut Sci Hlth Sci, Dept Radiopharmaceut Chem, Sapporo, Hokkaido 0610293, Japan
关键词
cyclooxygenase-2 (COX-2); inhibitor; radioiodination; SPECT; radiopharmaceutical;
D O I
10.1016/j.nucmedbio.2005.10.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Although several COX-2 inhibitors have recently been radiolabeled, their potential for imaging COX-2 expression remains unclear. In particular, the sulfonamide moiety of COX-2 inhibitors may cause slow blood clearance of the radiotracer, due to its affinity for carbonic anhydrase (CA) in erythrocytes. Thus, we designed a methyl sulfone-type analogue, 5-(4-iodophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-pyrazole (IMTP). In this study, the potential of radioiodinated IMTP was assessed in comparison with a I-125-labeled celecoxib analogue with a sulfonamide moiety (I-125-IATP). Methods: The COX inhibitory potency was assessed by measuring COX-catalyzed oxidation by hydrogen peroxide. The biodistribution of I-125-IMTP and I-125-IATP was determined by the ex vivo tissue counting method in rats. Distribution of the labeled compounds to rat blood cells was measured. Results: The COX-2 inhibitory potency of IMTP (IC50=5.16 mu M) and IATP (IC50=8.20 mu M) was higher than that of meloxicam (IC50-29.0 mu M) and comparable to that of SC-58125 (IC50=1.36 mu M). The IC50 ratios (COX-1/COX-2) indicated the high isoform selectivity of IMTP and IATP for COX-2. Significant levels of I-125-IMTP and 125 MATP were observed in the kidneys and the brain (organs known to express COX-2). The blood clearance of I-125-IMTP was much faster than that of I-125-IATP. Distribution of (125) I-IATP to blood cells (88.0%) was markedly higher than that of I-125-IMTP (18.1%), which was decreased by CA inhibitors. Conclusions: Our results showed a high inhibitory potency and selectivity of IMTP for COX-2. The substitution of a sulfonamide moiety to a methyl sulfone moiety effectively improved the blood clearance of the compound, indicating the loss of the cross reactivity with CA in I-125-IMTP. I-123-IMTP may be a potential SPECT radiopharmaceutical for COX-2 expression. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [1] SYNTHESIS AND EVALUATION OF A RADIOIODINATED COXIB AS A SPECT TRACER FOR CYCLOOXYGENASE-2 EXPRESSION
    Kuge, Y.
    Shimonaka, S.
    Katada, Y.
    Temma, T.
    Kimura, H.
    Kiyono, Y.
    Yokota, C.
    Minematsu, K.
    Seki, K-I.
    Tamaki, N.
    Ohkura, K.
    Saji, H.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S297 - S297
  • [2] A RADIOIODINATED LUMIRACOXIB DERIVATIVE: SYNTHESIS AND IN VITRO/IN VIVO EVALUATION AS A SPECT TRACER FOR CYCLOOXYGENASE-2 EXPRESSION
    Kuge, Y.
    Obokata, N.
    Kimura, H.
    Katada, Y.
    Temma, T.
    Sigimoto, Y.
    Aita, K.
    Seki, K.
    Tamaki, N.
    Saji, H.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2009, 52 : S121 - S121
  • [3] Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression
    Kuge, Yuji
    Obokata, Naoyuki
    Kimura, Hiroyuki
    Katada, Yumiko
    Temma, Takashi
    Sugimoto, Yukihiko
    Aita, Kazuki
    Seki, Koh-ichi
    Tamaki, Nagara
    Saji, Hideo
    NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (08) : 869 - 876
  • [4] Cyclooxygenase-2 inhibitors
    Nies, AS
    Gresser, MJ
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 115 - +
  • [5] Cyclooxygenase-2 inhibitors
    Gajraj, NM
    ANESTHESIA AND ANALGESIA, 2003, 96 (06): : 1720 - 1738
  • [6] Cyclooxygenase-2 inhibitors
    Terrett, N
    DRUG DISCOVERY TODAY, 1997, 2 (11) : 501 - 501
  • [7] Cyclooxygenase-2 inhibitors
    Hawkey, CJ
    Fortun, PJ
    CURRENT OPINION IN GASTROENTEROLOGY, 2005, 21 (06) : 660 - 664
  • [8] Cyclooxygenase-2 inhibitors
    Turnheim, K
    WIENER KLINISCHE WOCHENSCHRIFT, 2001, 113 (15-16) : 558 - 565
  • [9] Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors
    Molinari, Aurora
    Oliva, Alfonso
    Arismendi-Macuer, Marlene
    Guzman, Leda
    Acevedo, Waldo
    Aguayo, Daniel
    Vinet, Raul
    San Feliciano, Arturo
    MOLECULES, 2019, 24 (12):
  • [10] Nephrotoxic potential of selective cyclooxygenase-2 inhibitors
    Sandhu, GK
    Heyneman, CA
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (04) : 700 - 704